Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

PURPOSE: The anti-programmed death-1 (PD-1) antibody nivolumab (BMS-936558) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected stage IIIC and IV melanoma patients. EXPERIMENTAL DESIGN: HLA-A*0201 positive patients with...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Gibney, Geoffrey T., Kudchadkar, Ragini R., DeConti, Ronald C., Thebeau, Melissa S., Czupryn, Maria P., Tetteh, Leticia, Eysmans, Cabell, Richards, Allison, Schell, Michael J., Fisher, Kate J., Horak, Christine E., Inzunza, H. David, Yu, Bin, Martinez, Alberto J., Younos, Ibrahim, Weber, Jeffrey S.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4620684/
https://ncbi.nlm.nih.gov/pubmed/25524312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2468
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items